Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2930
Título : Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.
Autor : Kalincik, Tomas
Spelman, Timothy
Trojano, Maria
Duquette, Pierre
Izquierdo, Guillermo
Grammond, Pierre
Lugaresi, Alessandra
Hupperts, Raymond
Cristiano, Edgardo
Van Pesch, Vincent
Grand'Maison, Francois
La Spitaleri, Daniele
Rio, Maria Edite
Flechter, Sholmo
Oreja-Guevara, Celia
Giuliani, Giorgio
Savino, Aldo
Amato, Maria Pia
Petersen, Thor
Fernandez-Bolanos, Ricardo
Bergamaschi, Roberto
Iuliano, Gerardo
Boz, Cavit
Lechner-Scott, Jeannette
Deri, Norma
Gray, Orla
Verheul, Freek
Fiol, Marcela
Barnett, Michael
van Munster, Erik
Santiago, Vetere
Moore, Fraser
Slee, Mark
Saladino, Maria Laura
Alroughani, Raed
Shaw, Cameron
Kasa, Krisztian
Petkovska-Boskova, Tatjana
den Braber-Moerland, Leontien
Chapman, Joab
Skromne, Eli
Herbert, Joseph
Poehlau, Dieter
Needham, Merrilee
Bacile Bacile, Elizabeth Alejandra
Arruda, Walter Oleschko
Paine, Mark
Singhal, Bhim
Vucic, Steve
Cabrera-Gomez, Jose Antonio
Butzkueven, Helmut
Filiación: [Karkincic,T; Butzkueven,H] Departments of Medicine and Neurology, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia. [Spelman,T] Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia. [Trojano,M] Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy. [Duquette,P] Hòpital Notre Dame, Montreal, Canada. [Izquierdo,G] Hospital Universitario Virgen Macarena, Sevilla, Spain. [Grammond,P] Hotel-Dieu de Levis, Quebec, Canada. [Lugaresi,A] MS Center, Department of Neuroscience and Imaging, University ‘G. d’Annunzio’, Chieti, Italy. [Hupperts,R] Maaslandziekenhuis, Sittard, The Netherlands. [Cristiano,E] Hospital Italiano, Buenos Aires, Argentina. [Van Pesch,V] Cliniques Universitaires Saint-Luc, Brussels, Belgium. [Grand´Maison,F ]Neuro Rive-Sud, Hòpital Charles LeMoyne, Quebec, Canada. [La Spitaleri,D] AORN San Giuseppe Moscati, Avellino, Italy. [Rio,ME] Hospital S. Joao, Porto, Portugal. [Flechter,S] Assaf Harofeh Medical Center, Beer-Yaakov, Israel. [Oreja-Guevera,C] University Hospital San Carlos, IdISSC, Madrid, Spain. [Giuliani,G] Ospedale di Macerata, Macerata, Italy. [Savino,A] Consultorio Privado, Buenos Aires, Argentina. [Amato,MP] Department NEUROFARBA, Section of Neurology, University of Florence, Florence, Italy. [Petersen,T] Kommunehospitalet, Aarhus C, Denmark. [Fernandez-Bolanos,R] Hospital Universitario Virgen de Valme, Seville, Spain. [Bergamaschi,R] Neurological Institute IRCCS Mondino, Pavia, Italy. [Iuliano,G] Ospedali Riuniti di Salerno, Salerno, Italy. [Boz,C] Karadeniz Technical University, Trabzon, Turkey. [Lechner-Scott,J] John Hunter Hospital, Newcastle, Australia. [Deri,N] Hospital Fernandez, Buenos Aires, Argentina.[Gray,O] Craigavon Area Hospital, Portadown, United Kingdom. [Verheul,F] Groen Hart Ziekenhuis, Gouda, The Netherlands. [Fiol,M] FLENI, Buenos Aires, Argentina. [Barnett,M] Brain and Mind Research Institute, Sydney, Australia. [van Munster,E] Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, The Netherlands. [Santiago,V]HIGA Gral, San Martin La Plata, Argentina. [Moore,F] Jewish General Hospital, McGill University, Montreal, Canada. [Slee,M] Flinders University and Medical Centre, Adelaide, Australia. [Saladino,ML] INEBA, Buenos Aires, Argentina. [Alroughani,R] Amiri Hospital, Kuwait City, Kuwait. [Shaw,C] Geelong Hospital, Geelong, Australia. [Kasa,K] Jahn Ferenc Teaching Hospital, Budapest, Hungary. [Petkovska-Boskova,T] Clinic of Neurology Clinical Center, Skopje, Macedonia. [den Braber-Moerland,L] Francicus Ziekenhuis, Roosendaal, The Netherlands. [Chapman,J] Sheba Medical Center, Tel Hashomer, Israel. [Skromne,E] Hospital Angeles Mexico City, Lomas, Mexico. [Herbert,J] New York University Hospital for Joint Diseases, New York, New York, United States of America. [Poehlau,D] Multiple Sclerosis Centre Kamillus-Klinik, Asbach, Germany. [Needham,M] Royal North Shore Hospital, Sydney, Australi. [Bacile Bacile,EA] Instituto de Neurociencias Cordoba, Cordoba, Argentin. [Arruda,WO] Hospital Ecoville, Curitiba, Brazil. [Paine, M] St Vincent’s Hospital, Melbourne, Australia. [Sighal,B] Bombay Hospital Institute of Medical Sciences, Mumbai, India. [Vucic,S] Westmead Hospital, Sydney, Australia. [Cabrera-Gomez,JA] Centro Internacional de Restauracion Neurologica, Havana, Cuba. [Butzkueven,H] Department of Neurology, Box Hill Hospital and Monash University, Melbourne, Australia.
Grupo de Investigación: The MSBase Study Group
Palabras clave : Interferón beta
Relación dosis-respuesta a droga
Inyecciones subcutáneas
Funciones de verosimilitud
Esclerosis múltiple
Espectroscopía de resonancia magnética
Reproducibilidad de los resultados
Resultado del tratamiento
Privación del tratamiento
Adulto
Esclerosis múltiple
Cumplimiento y adherencia al tratamiento
MeSH: Medical Subject Headings::Disciplines and Occupations::Social Sciences::Demography
Medical Subject Headings::Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Dose-Response Relationship, Drug
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Schedule
Medical Subject Headings::Check Tags::Female
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Routes::Injections::Injections, Subcutaneous
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Interferons::Interferon Type I::Interferon-beta
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Kaplan-Meier Estimate
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models, Statistical::Likelihood Functions
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Magnetic Resonance Imaging
Medical Subject Headings::Check Tags::Male
Medical Subject Headings::Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Health Behavior::Patient Compliance::Medication Adherence
Medical Subject Headings::Diseases::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Propensity Score
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Research Design::Reproducibility of Results
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Withholding Treatment
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult
Fecha de publicación : 21-May-2013
Editorial : Public Library of Science
Cita Bibliográfica: Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, et al. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS ONE. 2013; 8(5):e63480
Abstract: OBJECTIVES To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. METHODS Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 µg or 44 µg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded. RESULTS Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as "lack of efficacy" (3.3% vs. 1.7%), "scheduled stop" (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 µg vs. 44 µg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages. CONCLUSIONS Treatment discontinuations were more common in interferon β-1a 22 µg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from "real-world" database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry.
Descripción : Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't;
URI: http://hdl.handle.net/10668/2930
Versión del editor : http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0063480#abstract0
DOI: 10.1371/journal.pone.0063480
ISSN : 1932-6203 (Online)
Appears in Collections:01- Artículos - Hospital de Valme
01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
KalincikT_PersistenceTherapyPropensity.PDFArtículo publicado370,54 kBAdobe PDFView/Open


Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.